A nanoparticle’s performance depends on more than what it is made of—it can also depend on how its building blocks are arranged. When nanoparticles are organized into carefully designed structures, their interactions can produce stronger signals and bring different sensing functions together. This design principle is attracting interest for disease biomarker detection , where early-stage biomarkers may occur at low concentrations and clinical samples contain many interfering substances. A review in Biomedical Analysis by researchers from Shandong University , China, examines how these structural design strategies are being used to advance disease biomarker detection.
Nanoparticles are widely used in biosensing for their optical, electronic, and catalytic properties. When assembled into superstructures, their collective interactions can enhance existing properties or generate new ones. The review distinguishes two key approaches: single-component assembly , in which different arrangements of the same building blocks produce distinct material properties, and multicomponent co-assembly , which combines different materials to achieve functional integration and synergistic effects. For example, self-assembled Cu 2 O superstructures can enhance Raman scattering through copper-vacancy defects that promote charge-transfer interactions and facilitate the adsorption of target molecules. Combining gold nanoparticles with metal–organic frameworks can also integrate molecular capture and signal generation, enabling sensitive detection of gaseous analytes. These examples illustrate how controlling nanoscale structure can enhance existing material properties or combine complementary functions.
One example involves surface-enhanced Raman scattering (SERS), a technique that identifies molecules through their characteristic vibrational signatures, but its sensitivity depends heavily on electromagnetic hotspots. The review highlights a DNA tetrahedron-guided approach that organizes gold nanoparticles into core–satellite superstructures with controlled interparticle spacing. By strengthening electromagnetic coupling between neighboring particles, the platform achieved a reported detection limit of 1.97 picomolar for microRNA-21, a disease-associated biomarker. Beyond Raman sensing, the review also describes how structural organization can regulate fluorescence energy transfer, enhance electrochemiluminescence, and improve catalytic activity for colorimetric detection. Together, these examples demonstrate how the arrangement of nanoscale components can influence analytical performance through different mechanisms.
Superstructured nanomaterials can also combine complementary sensing functions within a single platform. The review describes a dual-mode sensor for cystatin C, a biomarker associated with kidney function, using DNA tetrahedron-mediated hierarchical assembly of gold nanoparticles for colorimetric and fluorescence detection. The reported colorimetric detection limit improved from 250 to 25 ng/mL, while the fluorescence mode achieved 5 ng/mL. The two methods provide complementary readouts, combining visual detection with more sensitive fluorescence measurement. The platform was further evaluated using 40 clinical serum samples, with results showing a strong correlation with the reference particle-enhanced turbidimetric immunoassay (PETIA) method. The review also discusses other multimodal platforms integrating colorimetric, electrochemiluminescence, fluorescence, and Raman signals. However, challenges such as structural defects, assembly reproducibility, long-term stability, and performance in complex biological samples remain important considerations for clinical translation.
The review highlights how precise nanoparticle assembly could support the development of more sensitive and versatile biosensors. Turning these advances into reliable biomedical tools, however, will require reproducible fabrication, stable sensing performance, and further validation in complex clinical samples.
DOI： 10.1016/j.bioana.2026.09.002
Read the full article: https://www.sciencedirect.com/science/article/pii/S2950435X26000314
Biomedical Analysis invites submissions for its 2026 Special Issue, “POCT Technology Innovation and Application.” The issue welcomes original research articles and reviews on innovative point-of-care testing (POCT) technologies, materials and device development, multi-scenario applications, and intelligent and digital POCT.
The submission deadline is December 31, 2026 . Please refer to the Guide for Authors to prepare your manuscript and select the article type “VSI: POCT Technology Innovation and Application” when submitting your manuscript online.
Submit your manuscript at: https://www2.cloud.editorialmanager.com/bioana/default2.aspx
Biomedical Analysis is an international, peer-reviewed, open access journal published by Elsevier and KeAi and jointly sponsored by Sun Yat-sen University and the Guangzhou Analysis and Testing Center.
The journal publishes high-quality research in biomedical engineering, bioanalytical chemistry, biochemistry, genetics, biology, biomaterials, medicine, and related interdisciplinary fields, with a particular focus on biomedical testing, sensing technologies, and analytical innovation. Biomedical Analysis is indexed in Scopus, CAS, DOAJ, and EBSCO. Article processing charges (APCs) are currently waived for accepted manuscripts through the end of 2026.
Journal website: https://www.sciencedirect.com/journal/biomedical-analysis .
Biomedical Analysis
Literature review
Not applicable
Superstructured nanomaterials for disease biomarker detection: Design principles and analytical modalities
29-Sep-2026
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.